CIKS Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application ![]()
| WB, IHC-P, IF, E |
---|---|
Primary Accession | O43734 |
Other Accession | O43734, 10758 |
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | IgG |
Calculated MW | 63 kDa |
Application Notes | CIKS antibody can be used for detection of CIKS by Western blot at 1 μg/mL. A band at approximately 63 kDa can be detected. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL. |
Gene ID | 10758 |
---|---|
Other Names | CIKS Antibody: ACT1, CIKS, C6orf2, C6orf4, C6orf5, C6orf6, CANDF8, PSORS13, Adapter protein CIKS, Nuclear factor NF-kappa-B activator 1, ACT1, TRAF3 interacting protein 2 |
Target/Specificity | CIKS antibody was raised against a 14 amino acid peptide near the amino terminus of human CIKS. The immunogen is located within the first 50 amino acids of CIKS. |
Reconstitution & Storage | CIKS antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
Precautions | CIKS Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | TRAF3IP2 (HGNC:1343) |
---|---|
Function | E3 ubiquitin ligase that catalyzes 'Lys-63'-linked polyubiquitination of target protein, enhancing protein-protein interaction and cell signaling (PubMed:19825828). Transfers ubiquitin from E2 ubiquitin-conjugating enzyme UBE2V1-UBE2N to substrate protein (PubMed:19825828). Essential adapter molecule in IL17A-mediated signaling (PubMed:19825828, PubMed:24120361). Upon IL17A stimulation, interacts with IL17RA and IL17RC receptor chains through SEFIR domains and catalyzes 'Lys-63'-linked polyubiquitination of TRAF6, leading to TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways (PubMed:19825828). |
Tissue Location | Widely expressed. |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
CIKS Antibody: Nuclear factor kappa B (NF-κB) is a ubiquitous transcription factor and an essential mediator of gene expression during activation of immune and inflammatory responses. NF-κB mediates the expression of a great variety of genes in response to extracellular stimuli. NF-κB associates with IκB proteins in the cell cytoplasm, which inhibit NF-κB activity. IκB is phosphorylated by IκB kinase (IKK) complex that contains IKKα, IKKβ, and IKKγ. A novel molecule that associates with and activates IKK was recently identified and designated CIKS (for connection to IKK and SAPK/JNK) and Act1 (for NF-κB activator 1). CIKS directly interacts with IKKγ. CIKS/Act1 also activates activating transcription factor (ATF) and activator protein 1 (AP-1) through Jun kinase (JNK). These results indicate that CIKS/Act1 is involved in the inflammation and stress responses. CIKS/Act1 is ubiquitously expressed in human tissues.
References
Leonardi A, Chariot A, Claudio E, Cunningham K, Siebenlist U. CIKS, a connection to Iκ B kinase and stress-activated protein kinase. Proc Natl Acad Sci USA. 2000;97(19):10494-9.
Li X, Commane M, Nie H, Hua X, Chatterjee-Kishore M, Wald D, Haag M, Stark GR. Act1, an NF-κ B activating protein. Proc Natl Acad Sci USA. 2000;97(19):10489-93.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.